A股今日上市 康希諾港股一度跌近10% 月內累跌26%
格隆匯8月13日丨康希諾生物-B(6185.HK)近期持續走低,今日盤中一度跳水跌9.67%報187.7港元,暫成交3億港元,最新總市值775億港元。該股月內已累跌26%。康希諾A股今日在科創板首日上市,發行價為209.71元(約233.74港元),一度高開124%,目前漲幅收窄至約91%報402元(約449港元)。業內人士指出,近期康希諾港股的持續下跌走勢,除了科創板上市利好已提前被市場消費外,近期疫苗股的整體疲弱是大背景。在經過此前的持續上漲後,疫苗股本身交易層面出現調整需求,而基本面,新冠疫苗雖然未來會有超400億的空間,但並不會是短期內能實現的。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.